MORGAN STANLEY - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2021$1,232,000
-57.0%
1,339,000
-55.9%
0.00%
Q2 2021$2,865,000
-7.3%
3,039,0000.0%0.00%
Q1 2021$3,092,000
-27.3%
3,039,000
-33.0%
0.00%
-100.0%
Q4 2020$4,252,000
+59.6%
4,539,000
+51.9%
0.00%0.0%
Q3 2020$2,664,000
-14.6%
2,989,000
-9.5%
0.00%0.0%
Q2 2020$3,118,000
+29.4%
3,304,000
+40.4%
0.00%0.0%
Q1 2020$2,409,000
-48.0%
2,354,000
-48.2%
0.00%0.0%
Q4 2019$4,630,000
+61.3%
4,544,000
+46.9%
0.00%0.0%
Q3 2019$2,871,000
-28.7%
3,094,000
-33.4%
0.00%0.0%
Q2 2019$4,028,000
-19.5%
4,644,000
-9.7%
0.00%0.0%
Q1 2019$5,003,000
+22.3%
5,144,000
+28.6%
0.00%0.0%
Q4 2018$4,092,000
-37.4%
4,000,000
-27.6%
0.00%
-50.0%
Q3 2018$6,536,000
+4.1%
5,528,000
-12.9%
0.00%0.0%
Q2 2018$6,280,000
+3024.4%
6,348,000
+3074.0%
0.00%
Q1 2018$201,000
-8.2%
200,0000.0%0.00%
Q4 2017$219,000
-94.1%
200,000
-93.3%
0.00%
-100.0%
Q3 2017$3,683,000
-9.0%
3,000,0000.0%0.00%0.0%
Q2 2017$4,049,0003,000,0000.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Context Capital Management, LLC 25,388$23,544,0002.40%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 49,675,000$46,013,0001.22%
DeepCurrents Investment Group LLC 33,824,000$31,165,0000.93%
Aequim Alternative Investments LP 13,920,000$12,909,0000.50%
Maven Securities LTD 14,280,000$14,280,0000.46%
Saltoro Capital, LP 1,350,000$1,252,0000.44%
Baupost Group 30,000,000$27,640,0000.25%
TENOR CAPITAL MANAGEMENT Co., L.P. 5,500,000$5,182,0000.12%
ZAZOVE ASSOCIATES LLC 1,250,000$1,163,0000.10%
HBK INVESTMENTS L P 22,500,000$20,832,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders